Joy Burchell

Guy's Hospital — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

66h-index15.4kcitations236works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glycosylation and Glycoproteins Research(138), Monoclonal and Polyclonal Antibodies Research(86), Immunotherapy and Immune Responses(45), Carbohydrate Chemistry and Synthesis(45), Galectins and Cancer Biology(38)

Publications236 total

A mucin degrader for cancer therapy
Nature Biotechnology·2023· 2 cited
LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer
Developmental Cell·2023· 50 citedOpen Access
Data from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplemental Figure 1: HLAII-DR molecule accumulates at the periphery of DCs after 12 hours incubation from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplementary Figure 2 - PDF file - 3056K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplemental Figure 1: HLAII-DR molecule accumulates at the periphery of DCs after 12 hours incubation from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplementary Figure 1 - PDF file - 42K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplementary Figure 1 - PDF file - 42K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Data from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplemental Figure 2: Characterization of MUC1-DG75 transfectant cell line and of the MUC1-DG75-MVs. from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplemental Figure 2: Characterization of MUC1-DG75 transfectant cell line and of the MUC1-DG75-MVs. from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplementary Figure 2 - PDF file - 3056K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
2023Open Access
Supplementary Table from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
2023Open Access
Supplementary Table from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
2023Open Access
Supplementary Figures 1-10, Supplementary Materials and Methods, Supplementary References from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
2023Open Access
Data from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
2023Open Access
Supplementary Table from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
2023Open Access
Supplementary Figures 1-10, Supplementary Materials and Methods, Supplementary References from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
2023Open Access
Data from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
2023Open Access
Supplementary Table from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Joyce Taylor‐Papadimitriou(41), Henrik Clausen(13), Ulla Mandel(8), Sandra Gendler(7), Michael A. Hollingsworth(7), Richard Beatson(6), Gianfranco Picco(6), Eric Bennett(6), Trevor Duhig(5), Sylvain Julien(5), Inka Brockhausen(4), Caroline A. Whitehouse(4), Julia Coleman(4), Peter Roepstorff(4), Celso A. Reis(4), David Miles(3), Martin Dalziel(3), Thomas Noll(3), Lucienne Cooper(3), Helle Hassan(3)